异基因造血干细胞移植在NHL治疗中的地位文档64页.pptVIP

1982-2019NHL 自体与异基因移植比较（ EBMT ） AJ Peniket An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous Transplantation. Bone Marrow Transplantation (2019) 31, 667 – 678 38% 41% 37% 25% 1982-2019NHL 自体与异基因移植比较（ EBMT ） 结论： ? 异基因移植折高 TRM 抵消了低复发率 ? 异基因移植折确切作用有待于进一步研究 AJ Peniket An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous Transplantation. Bone Marrow Transplantation (2019) 31, 667 – 678 TRM TRM allo-HSCT 治疗侵袭性淋巴瘤 Norbert Schmitz, Peter Dreger.Allogeneic transplantation in lymphoma: current status 。 Haematologica 2019; 92:1533-1548. 0 20 40 60 80 100 P r o b a b i l i t y , % Chemo-sensitive, Myeloablative (N=214) 0 2 6 1 3 Years 4 5 Probability of Survival after HLA-identical Sibling Transplants for Diffuse Large Cell Lymphoma,2019-2019 - by Disease Status and Conditioning Regimen - P = 0.011 Chemo-sensitive, RIC (N=56) Chemo-resistant, Myeloablative (N=75) Chemo-resistant, RIC (N=26) RIC = Reduced Intensity Conditioning 0 20 40 60 80 100 P r o b a b i l i t y , % Auto (N=1,202) 0 2 6 1 3 Years 4 5 Probability of Survival after Transplants for Mantle Cell Lymphoma, 2019-2019 - by Donor Type and Conditioning Regimen - P 0.001 HLA-id sib, RIC (N=111) unrelated, RIC (N=60) HLA-id sib, Myeloablative (N=205) Unrelated, Myeloablative (N=46) 1990-2019 年日本 233 名 NHL Allo-SCT 结果 ? 154 名 (66%)HLA 相合，无关供者 60 名 (26%).90 人 (39%)CR.193 人 (83%) 预处理含 TBI Kim SW, Tanimoto TE, Hirabayashi N, Goto S, et al. Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood 2019;108:382-9. 36:205-13 . 42% 39% 21% 1990-2019 年日